Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks

뉴스 본문을 불러오고 있어요.

Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks | 웨이프 WAPE

Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks

기사 요약

관련 종목

댓글 —